Revvity (0KHE)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 156.45 |
|---|---|
| 52-week range | 80.00 – 167.56 |
| Return, 1 month / 3 months | +10.4% / +38.6% |
| Return, 1 year / 3 years | +59.9% / +52.6% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 39.8% |
| Worst drawdown (1 year) | -30.9% |
| Average daily value traded | 0.08M USD |
| Dividend yield | 0.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Revvity is a life sciences and diagnostics company based in Waltham, Massachusetts. It supplies instruments, reagents, assay platforms, informatics software and services used in drug discovery, research and clinical testing. Its customers include pharmaceutical and biotechnology companies, clinical laboratories, hospitals and academic research institutions. The company's work spans areas such as screening, imaging, sample preparation and diagnostic testing, helping laboratories generate and interpret scientific and medical data.
The shares are listed on the London Exchange in UK under the code 0KHE, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Revvity (0KHE) trades on the London Exchange in UK. It last closed at USD 156.45 on 23 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 953 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 59.9% and over the last three months it rose 38.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 43.3% | ||
| From 52-week high | 0.0% | ||
| Momentum | 93 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 38.6% | ||
| 6-month return | 86.4% | ||
| 12-month return, skipping the last month | 44.8% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.9% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.08M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 21 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.4% |
|---|---|
| 1 month | +10.4% |
| 3 months | +38.6% |
| 6 months | +86.4% |
| 1 year | +59.9% |
| 3 years | +52.6% |
| 5 years | −10.0% |
Signals
| 50-day / 200-day average | 136.47 / 109.16 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.91 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Jul 2026 | USD 0.0700 |
| 16 Apr 2026 | USD 0.0700 |
| 15 Jan 2026 | USD 0.0700 |
| 16 Oct 2025 | USD 0.0700 |
| 17 Jul 2025 | USD 0.0700 |
| 16 Apr 2025 | USD 0.0700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.